SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Pictured: Novavax/Getty Images, STR/NurPhoto
Business
Novavax Hit Hard by Late Vaccine, while BioNTech Touts Variant-Adapted Shots
Novavax released its second quarter financial results, showing a dramatic adjustment in its sales outlook, while BioNTech prepares to launch two variant-adopted bivalent shots.
August 9, 2022
 · 
3 min read
 · 
Tristan Manalac
Leon Neal/Getty Images
Business
GSK Ups Ante in ADC Discovery Game with $1.4B Mersana Option Deal
Mersana unveiled a global collaboration with GSK, which gives GSK the exclusive option to co-develop and commercialize Mersana’s antibody-drug conjugate XMT-2056.
August 9, 2022
 · 
3 min read
 · 
Tristan Manalac
KarXT can be the new hope for schizophrenia patien
Drug Development
Karuna’s KarXT Drug Could Signal New Hope for Schizophrenia - Updated
Karuna Therapeutics released results from the Phase III EMERGENT-2 trial showing that KarXT, its lead candidate, can strongly reduce symptom severity in schizophrenia patients.
August 8, 2022
 · 
3 min read
 · 
Tristan Manalac
A Question of Life and Death: Yale Scientists Bring Pig Organs Back to Life
If replicated in humans, this technology could prolong organ health during major surgeries and improve the availability of donor organs.
August 8, 2022
 · 
3 min read
 · 
Tristan Manalac
Michel Stoupak/NurPhoto via Getty Images
Business
Sanofi Expands China Footprint with Innovent Collaboration
The agreement will grant Innovent exclusive development and marketing rights to tusamitamab in China, while Sanofi will be entitled to up to $81 million in milestones and royalties.
August 5, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Yuki Iwamura/AFP via Getty Images
Drug Development
U.S. Regulators Announce Plans for Monkeypox Antiviral Trial
Experts from U.S. health regulatory agencies have announced plans to conduct a clinical trial to assess the safety and efficacy of TPOXX (tecovirimat) as an antiviral for monkeypox.
August 4, 2022
 · 
2 min read
 · 
Tristan Manalac
An old man looking at camera, covering his mouth with his hand. Black and white photo.
Drug Development
Two New Triggers for Alzheimer’s Identified: What Does it Mean?
Researchers have found that two common viruses—the varicella zoster and herpes simplex viruses—likely constitute a pathway that leads to Alzheimer’s disease.
August 4, 2022
 · 
3 min read
 · 
Tristan Manalac
Pictured: Alnylam CEO Yvonne Greenstreet, Alnylam
Drug Development
Alnylam Adds Amyloidosis Candidate to Growing List of Wins
Alnylam revealed its Phase III APOLLO-B study, which showed that patisiran improves both functional capacity and quality of life in patients with ATTR amyloidosis with cardiomyopathy.
August 3, 2022
 · 
3 min read
 · 
Tristan Manalac
As Healthcare Crises Pile Up, Pharma Struggles to Meet Demand - Updated
As the world faces one public health crisis after another, it seems that pharmaceutical companies across the board are having trouble keeping up with the ever-growing need for medicines.
August 3, 2022
 · 
4 min read
 · 
Tristan Manalac
Sarah Silbiger/Getty Images
Drug Development
FDA Presses Play on Celyad and Pause on Beam for Cancer Candidates
The FDA has placed a clinical hold on Beam Therapeutics’ leukemia/lymphoma therapy and has lifted the hold on Celyad’s CAR-T candidate for colorectal cancer.
August 2, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Kazia’s Star Asset Suffers Surprise Letdown in Global Glioblastoma Study
The exact implications of the paxalisib disappointment are still unclear, though it is highly likely that the candidate will be dropped from the GBM AGILE umbrella trial.
August 2, 2022
 · 
3 min read
 · 
Tristan Manalac
Pictured: Stop sign in front of FDA headquarters/S
Drug Development
Nuvation Down to Last Drug in Pipeline After Dropping Glioma Candidate
The decision comes after the FDA put NUV-422, its candidate for high-grade gliomas, on a partial clinical hold, citing safety concerns.
August 1, 2022
 · 
2 min read
 · 
Tristan Manalac
Marengo CEO Dr. Zhen Su, M.D./Courtesy of Marengo
Business
Ipsen Invests Potential $1.6B to Turbo-Charge Marengo’s Path to the Clinic
Marengo Therapeutics and Ipsen have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.
August 1, 2022
 · 
3 min read
 · 
Tristan Manalac
With Some Help, Small Canadian Biotech Could Challenge Roche’s Hold in Stroke Treatment
NervGen showed that its proprietary drug NVG-291-R, could repair the nervous system after a stroke in rodents —even when it was given seven days after the episode.
July 29, 2022
 · 
3 min read
 · 
Tristan Manalac
Monkey pox vesicles in a hand
Policy
San Francisco, New York Declare Local Health Emergencies Over Monkeypox
The measures will allow San Francisco and New York to coordinate efforts across different agencies and raise the public’s awareness to curb the spread of monkeypox.
July 29, 2022
 · 
2 min read
 · 
Tristan Manalac
Load More